Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
A philosophy rooted in technological innovation
Since 1995, Oncodesign has been innovating to discover new therapies for cancers and diseases with no known treatment.
Scientific and commercial support for drug discovery
Integrated services in drug discovery | Services BU
State-of-the-art expertise available throughout the whole process, from hit finding to the IND, so you can discover and test your innovative therapies
Innovative technological approaches | Biotech BU
Innovative technologies and partnerships so your therapeutic programs can make progress
Artificial Intelligence tools | AI BU
Hybrid AI and Drug Discovery expertise for a faster and more reliable drug candidate search process
Homing : a preclinical co-development program for your molecule
Combined expertise to speed up your oncology and immuno-oncology research & development programs
Our innovation technologies optimize your drug discovery programs to make them faster and more reliable
For more than 25 years, Oncodesign has been investing in precision medicine research technologies, which are essential from the very first stages of the Drug Discovery process. Our technology modules allow a continuum from molecule to patient, with the goal of discovering new treatments for patients with no therapeutic options.
Science within easy reach!
Receive our monthly general newsletters or our biannual shareholder newsletter.
Oncodesign counts 230 employees worldwide.
Every one of them contributes to the success of our mission. Working at Oncodesign means helping in the quest for new drugs!
Make use of our resources to support your project
Find all our scientific documents, press releases, newsletters and news!
Investors
Access all stock market information and documents to track your investments
25/10/2021
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
21/10/2021
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
20/10/2021
[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar